icon

A couple of years ago shares of Geron Corporation (GERN) spiked to a near billion...

Read more

Shares of Human Genome Sciences (HGSI) are trading back to earth this week after having hit the fifteen dollar mark on talk of a buyout by Benlysta GlaxoSmithKline (GSK) last week. When the buyout talk, which originated in the UK with a newspaper article, failed to materialize into anything but rumo...

Read more

Already a stock to watch for weeks now thanks to some pending catalysts and volatile trading, Ampio Pharmaceuticals further solidified its pipeline potential this week by announcing favorable results for its trial in Australia testing its lead product Ampion for the treatment of osteoarthritis in th...

Read more

An eventful week just passed us by.

The NTC fighters in Libya finally caught up to Muammar Khaddafi and made history of the guy. That makes Saddam, Bin Laden and Khaddafi all toast. Who says the world doesn't become a better place every day?

Eyes perked up as well last week when numerous headline...

Read more

Shares of Keryx Biopharmaceuticals (KERX) have been in the spotlight ever since the company announced full enrollment for its Phase III Zerenex trial last month and KERX looked to be rebounding from its recent lows.

Now, some recent high-profile debating between popular biotech blogging sites has lau...

Read more

With a buyout rumor reversing a downward trend and leading to a sharp increase in volume and share price, shares of Human Genome Sciences (HGSI) have been in the spotlight all week long.

The buyout rumor was sparked earlier this week when a newspaper report in the UK identified GlaxoSmithKline (GSK)...

Read more

The Cytosorbents story continues to grow with the company announcing the "launch" of HemoDefend for application in the blood transfusion process.

Long followed by VFC's Stock House for the market potential of its blood purification technology, Cytosorbents happened upon a blockbuster event earlier this year when the European medical regulators granted CE Mark Approval CytoSorb in the treatment of indications where high cytokines are present in the bloodstream.

That news sent company shares into the forties, but that spike did not last and CTSO is again back to trading in the teens. Some out there are skeptical of the CytoSorb technology, given the small size of the European trial, while others recognize that it is going to take time for this small company to launch its newly-approved device in the methodical manner outlined by the CEO months ago.

Read more

Sometimes I wonder how we can take ourselves seriously.

In politics, for instance, politicians from the same party rip each other apart and slag each other in the media during primary season. The negative ads come out against members of their own party, which lessens the chances that the primary win...

Read more

GlaxoSmithKline (GSK) made historic news on Tuesday when it was announced that data from a clinical trial in Africa has shown that the company's experimental malaria vaccine halved the risk of African children getting malaria. Data from the study, according to reports released Tuesday afternoon, "sh...

Read more

Stock Watch Update: HGSI

Posted by Posted by VFC on Oct 18, 2011

This morning we discussed the positive after-hours and pre-market trading of HGSI on Monday evening and Tuesday morning, respectively, and it turns out that Tuesday's regular-hours trading followed suit.

The spike in share price was born on rumors from the UK that Human Genome's partner for Benlysta,...

Read more

Stock Watch Tuesday: HGSI

Posted by Posted by VFC on Oct 18, 2011

With earnings coming up, and given its recent slide, HGSI has been a stock to watch these past few weeks.

A positive earnings update last month caused a temporary spike in HGSI shares, but the general market downturn and a setback in the UK has had shares on the slide of late. That makes the upcoming...

Read more

Stocks and stories for the coming week...

SIRI: Shares of SiriusXM Satellite Radio closed higher on Friday by five percent, right at the buck-eighty mark, barely two weeks after a market downturn and some negative press pushed the stock to a low of $1.27 on high volume.

Since then, SiriusXM has furthe...

Read more

It's always good to see the Phillies take a seat on the couches during playoffs season - makes them just about as good as the Mets right now.

The classy fans in Philly never fail to live up to their rep either, as they booed Ryan Howard as he was being carried off the field after making the out that...

Read more

SIGA shares were hammered last month when a judge sided with PharmAthene (PIP) in regards to a failed merger years back. Although rebounding slightly to over three dollars, there's been no real move on the stock front, but Siga the company is moving forward to have the judge's decision overturned.

A ...

Read more

Pay attention to Biovest International, Inc. (BVTI.PK) this week.

The company will be presenting at the MD Becker Partners Cancer Immunotherapy Conference at the New York Academy of Medicine on October 6th.

Biovest, a subsidiary of Accentia Biopharmaceuticals (ABPI), has developed BiovaxID, a cancer i...

Read more

VFC's Take on news and notes from around the market, and a look at whether the rebound is real for various companies:

The Market Rebound: Tuesday and Wednesday were solid 'up' days for the market after Monday's fourth-quarter open left the world wondering just how much more punishment was in store.

VF...

Read more

Already beaten down as it was, the Cel-Sci (CVM) share price dropped again on Tuesday, but not necessarily because the entire market as a whole was still tanking.

In an effort to raise some more money to complete the ongoing global trial for Cel-Sci's Phase III head and neck cancer immunotherapy, Mul...

Read more

Is The Rebound For Real?

Posted by Posted by VFC on Oct 05, 2011

The fourth quarter opened up this week with the same thud heard during the closing days of the third, but after a quick slam on Tuesday morning that saw the DOW drop another two hundred points, a turnaround played out and the markets actually closed well in the green.

The reversal of fortune - quite ...

Read more

The market is dropping all around us, and it's taking with it many of the stocks that we've watching for years.

Shares of Advanced Cell Technology (OTCBB: ACTC) had been trading for months between seventeen and nineteen cents before trading down with the market towards the end of the third quarter an...

Read more

Agenus Effects Reverse Split

Posted by Posted by VFC on Oct 02, 2011

The transformation of Agenus Inc. continues.

Known for years as Antigenics, the company changed its profile to usher in the new year of 2011 by issuing itself the new name of Agenus Inc. and also renaming its flagship product, the cancer immunotherapy treatment Oncophage, as Prophage.

Oncophage was a...

Read more

The years-long wait continues for BioElectronics in its progress with achieving over-the-counter (OTC) status with the US FDA, but the company has taken advantage of 2011 and launched some new products in addition to initiating more clinical studies.

The Smart Insole was announced and released to sel...

Read more

The third quarter closed with a thud on Friday, with the DOW dropping another 240 points and closing below the eleven thousand mark, leaving investors looking towards the fourth quarter with apprehension about what else is in store for the shaky markets and global economy.

With feelings of uncertaint...

Read more